Home

If you have registered for this conference, please click this link to login and join. Your login details should have been sent to you by portal@smi-online.co.uk

3D Cell Culture

SAE Media Group’s 5th Annual Conference
3D Cell Culture
February 09-10, 2022 | Virtual Conference
-------------------------------------------------------------------------
3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to reach a value of $3.2 Billion by 2027, researchers globally are realising the growing potential of in vitro applications for drug discovery, predictivity and validation, safety and toxicity. 3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process -- heralding the next major advance in the discovery of pharmaceuticals.

Rising demand for tissue engineering for the treatment of chronic diseases is another key driver of this research -- new technologies in the form of organ-on-chip, microphysiological systems and 3D bioprinting are all burgeoning areas of the field.

Join us in February 2022, as SAE Media Group’s 5th annual 3D Cell Culture Conference brings together industry experts from big pharma, regulatory bodies, and biotech companies to discuss the challenges and drivers of these medical technologies, through case studies of the latest innovations in 3D Cell Culture models, real world examples of applications of new technologies, and insights into 3D bioinks and high throughput screening to give a comprehensive look into this fast growing industry.
yalsadoon@SAE Media Group-online.co.uk

FEATURED SPEAKERS

Anne Rios

Anne Rios

Principal Investigator/ Head of the PMC imaging center, The Princess Maxima Center of Pediatric Oncology
BanuPriya Sridharan

BanuPriya Sridharan

Investigator, GSK
Caroline Archer

Caroline Archer

Associate Principal Scientist, AstraZeneca
Catherine Vickers

Catherine Vickers

Head of Innovation, NC3Rs
Darren Heywood

Darren Heywood

Product Manager, Promega UK Ltd
Elisa Budyn

Elisa Budyn

Mechanical Engineering, Ecole Normale Supérieure Paris-Saclay
Freddy Van Goethem

Freddy Van Goethem

Scientific Director, Fellow, Janssen (Johnson & Johnson)
Hansjoerg Keller

Hansjoerg Keller

Senior Principal Scientist, Novartis Institutes for BioMedical Research
Isabella Bondesson

Isabella Bondesson

Field Application Specialist, CELLINK
Jason Ekert

Jason Ekert

Senior Director and Head of Complex In Vitro Models, GlaxoSmithKline
Julian Bahr

Julian Bahr

Senior Scientist, AstraZeneca
Lisa Sassi

Lisa Sassi

Scientist, Engitix Therapeutics
Louis Scampavia

Louis Scampavia

Scientific Director, Sr, Scripps Research
Lyle Armstrong

Lyle Armstrong

CSO Newcells Biotech and Professor of Stem Cell Sciences Newcastle University, Newcells Biotech Limited
Pedro Pinto

Pedro Pinto

Laboratory Lead, University of Greifswald – Medical Centre
Philip Hewitt

Philip Hewitt

Global head of early Investigative Toxicology, Merck Healthcare KGaA
Robert Vries

Robert Vries

CEO, Hubrecht Organoid Technology
Stefan Przyborski

Stefan Przyborski

Professor, Durham University
Stephen J. Fey

Stephen J. Fey

Founder and Chief Research Officer, Celvivo
Suzanne Fitzpatrick

Suzanne Fitzpatrick

SeniorAdvisor for Toxicology, FDA
Terry Van Vleet

Terry Van Vleet

Director of Investigative Toxicology, AbbVie

Anne Rios

Principal Investigator/ Head of the PMC imaging center, The Princess Maxima Center of Pediatric Oncology
Anne Rios

Anne Rios

Principal Investigator/ Head of the PMC imaging center, The Princess Maxima Center of Pediatric Oncology
Anne Rios

Dr. Anne Rios started her scientific career by developing and applying advanced imaging technologies to gain insight into developmental processes and stem cell biology (Nature 2011, Nature 2014). The Large-scale, Single-cell Resolution 3D (LSR-3D) imaging technology she developed allows for visualization of intact organs, tumors and organoids up to sub-cellular resolution and can reveal novel and unexpected features of both normal organ development and function, as well as cancer progression (Cancer Cell 2019, Nature Biotechnology 2021). As junior principal investigator and head of the imaging center at the Princess Máxima Center for Pediatric Oncology she combines her background in developmental biology and imaging expertise to drive discovery into the underlying mechanisms of childhood cancer and advance cellular immunotherapies for solid tumor targeting.

Photography credit: Photographer Barbara Kieboom (www.barbarakieboom.nl).

 

BanuPriya Sridharan

Investigator, GSK
BanuPriya Sridharan

BanuPriya was trained as a tissue engineer and worked with Biomaterials and stem cell spheroids for her PhD. After a brief stint at Medimmune she was trained in high throughput screening at the Scripps Research Institute in Florida where she worked with scaling iPSC-derived neurons and pancreatic organoids for HTS. Currently as an investigator at GSK, she works with different research units for -developing context-specific complex in vitro models. Specifically, she works with high throughput scalable platform for combinatorial drug screening in non-small cell lung cancer models and NASH disease modeling using liver-on-a-chip platforms.

 

Caroline Archer

Associate Principal Scientist, AstraZeneca
Caroline Archer

Caroline Archer obtained her PhD in 2013 at the University of Cambridge investigating the molecular mechanisms required for the induction of cardiac hypertrophy. After a few years in the biotechnology industry, she joined AstraZeneca as part of the Clinical Pharmacology and Safety Sciences department. Here, she has lead the development of a 3D cardiac microtissue model which is now utilised as a high-throughput front line safety screen. Caroline has a keen interest in the development of advanced in vitro cardiovascular models to help accelerate the replacement and reduction of animal studies in drug development.

 

Catherine Vickers

Head of Innovation, NC3Rs
Catherine Vickers

Dr Cathy Vickers

Cathy is Head of Innovation at the National Centre for the Reduction, Refinement and Replacement of animals in research (NC3Rs). Cathy leads the CRACK IT Challenges programme- an open innovation funding programme that brings large industry, academia and the SME sector together to accelerate the development and delivery of novel tools and technologies that improve R&D and reduce the reliance on animal models. Cathy holds a PhD in Neurophysiology from the University of Edinburgh.
 

Darren Heywood

Product Manager, Promega UK Ltd
Darren Heywood

Darren received his PhD in Neurobiology from the University of Bristol in 2003. His research was focused on investigating the involvement of signaling pathways involved in mediating neuronal cell death. Currently, as a Product Manager at Promega UK, Darren manages the cell health portfolio and has a particular interest in tools to monitor 3D cell health. With the demand for more physiologically relevant models comes a need for more accurate and sensitive cell-based assays that can deliver reliable results in more complex 3D microtissues. Darren works to support customers who wish investigate cell health in both 2D and 3D cultures.

Elisa Budyn

Mechanical Engineering, Ecole Normale Supérieure Paris-Saclay
Elisa Budyn

Biography: Dr. Elisa Budyn is Professor of Mechanical Engineering at Ecole Normale Superieure de Paris-Saclay. She earnerd an Engineering diploma from E.S.T.P. in France and graduated her M.Sc. and Ph.D. from Northwestern University in 1999 and 2004. Dr. Budyn worked at CNRS LMSSMat Laboratory at Ecole Centrale Paris for one year, after which she joined the University of Illinois at Chicago Mechanical Engineering Department in 2005 as Assistant Professor and joined Ecole Normale Supérieure Paris-Saclay in 2013 as Professor. Her research focuses on bioengineering and mechanobiology of human tissues thanks to the design and implementation of organ-on-chip that enable 3D culture mechanical testing and concurrent computational modeling of cells and tissues such as bone, heart, skin, ligament or liver. She investigates human cell mechanotransduction in in vitro recellularized native tissues in conditions closely mimicking in vivo conditions as test beds for potential patient screening or cells treatments. Her research has been funded by NSF, AFOSR, CNRS, ANR-RHU, Synchrotron SOLEIL and the Farman Institute.

 

Freddy Van Goethem

Scientific Director, Fellow, Janssen (Johnson & Johnson)
Freddy Van Goethem

Freddy obtained his Ph.D. degree in Science at the Free University of Brussels (Belgium) in 1995. After his post-doc, he joined Janssen (Belgium) as a Study Director for In Vitro Genetic and Predictive toxicology. From 2003 to 2009, Freddy was the chairman of the Belgian Environmental Mutagen Society.
During his career, he was responsible for the identification and validation of new in vitro test systems to assess the safety profile of compounds in early drug development. Today, he’s heading the Cell Health Assessment group responsible for high throughput liability screening and the evaluation of advanced in vitro models.
 

Hansjoerg Keller

Senior Principal Scientist, Novartis Institutes for BioMedical Research
Hansjoerg Keller

Hansjoerg Keller is a Senior Principal Scientist in the Musculoskeletal Disease Area at Novartis Institutes for BioMedical Research in Basel, Switzerland.
He studied Biochemistry and graduated in Neurochemistry at the Swiss Federal Institute of Technology Zürich (ETHZ), Switzerland in 1988. During his postdoctoral fellowship at the Scripps Research Institute, La Jolla, CA, USA (Prof. J. Gottesfeld) and later at the University of Lausanne (Prof. W. Wahli), he elucidated the role of transcription factors in the regulation of gene transcription discovering PPAR nuclear receptors and their activation by fatty acids. In 1996, he joined Novartis leading different drug discovery projects including selective estrogen receptor modulators (SERMs) and sclerostin inhibitors for osteoporosis treatment, and selective androgen receptor modulators (SARMs) against muscle wasting. His current research focuses on exercise-regulated myokines as new drug targets for the development of novel therapies against muscle wasting diseases. To this end, his group is pioneering 3D bioprinting technologies for the engineering of functional human skeletal muscle tissue models that allow in vitro screening of compounds affecting muscle function such as force, endurance and fatigue.
 

Isabella Bondesson

Field Application Specialist, CELLINK
Isabella Bondesson

Jason Ekert

Senior Director and Head of Complex In Vitro Models, GlaxoSmithKline
Jason Ekert

Dr. Jason Ekert is Senior Director, GSK Fellow and Head of the Complex In Vitro Models (CIVM) group at GlaxoSmithKline. He is responsible for an integrated enterprise strategy for R&D applications of complex human-relevant and translatable complex in vitro models (eg Organoids, Microphysiological systems and bioprinting). Before joining GSK he worked at Janssen in biotherapeutic drug discovery. Jason received his PhD from Adelaide University. Post-doctoral training was performed at University of California, Davis and Coriell Institute for Medical Research. He’s currently the chair for the IQ-MPS affiliate. He is a member of the Society for Lab Automation and Screening (SLAS) and Society of Toxicology (SOT).

Julian Bahr

Senior Scientist, AstraZeneca
Julian Bahr

Julian Bahr has been a Postdoctoral Fellow at AstraZeneca since 2018, where he is developing new 3D models for immunotherapy target discovery. His scientific training began at the National Institutes of Health under Dr. Susan Bates studying the mechanisms of HDAC and MAPK pathway inhibitors on KRAS mutant cancers. He went on to research macrophage-mediated basement membrane remodeling with Dr. Stephen Weiss for his Ph. D. work at the University of Michigan. Julian is passionate about elevating Ph.D. and Postdoctoral science and has continuously held leadership positions in the research organizations he has been a part of.

Lisa Sassi

Scientist, Engitix Therapeutics
Lisa Sassi

Before graduating from Politecnico of Milan (Italy) with a MSc Honours degree in Biomedical Engineering, Lisa joined the laboratory of Liver Engineering of Dr. Urbani, in collaboration with King’s College and UCL (London, UK): her work was focused on the development of bioreactor systems able to support the generation of humanized 3D bioengineered liver tissues, recapitulating features of liver fibrosis. Working in the field of tissue engineering, exposed Lisa to a multidisciplinary approach, on one hand gaining knowledge of traditional engineer skills, such as developing processes suitable for Good Manufacturing Procedures (GMP), automation and computer-aided design software (SolidWorks), on the other hand cell and molecular biology. Her current role in Engitix is Scientist, part of the Biomaterial Development team, where she is focused on the development of a portfolio of programmes in fibrosis and solid tumours using the proprietary human extracellular matrix (ECM)-based discovery platform to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates.

Louis Scampavia

Scientific Director, Sr, Scripps Research
Louis Scampavia

Dr. Louis Scampavia is a faculty member at Scripps Research within the Department of Molecular Medicine and a senior scientific director of High Throughput Screening (HTS). The Scripps Molecular uHTS Center is focused on drug discovery to support academic investigators and industrial partners, and its directors Drs. Louis Scampavia and Timothy Spicer leverage over four decades of biomedical research experience. Aside from performing large library uHTS screens, the directors also pursue technology development including the use of 3D cancer screening in high density 1536w plate format for precision medicine drug repurposing testing as well as uHTS drug discovery efforts.

 

Lyle Armstrong

CSO Newcells Biotech and Professor of Stem Cell Sciences Newcastle University, Newcells Biotech Limited
Lyle Armstrong

Professor Armstrong founded a contract research organisation developing and licensing diagnostic systems to identify and enumerate bacteria in biological fluids. This organisation was successful in generating a range of products that were subsequently licensed to industry and marketed as microbial diagnostic tools.
Prof Armstrong’s highly respected research group is focussed on reprogramming cells to hiPSCs and developing organoid and other complex models of human tissues. A key aspect of this investigation is researching the possible reversal of ageing during the reprogramming process and how this might be valuable for repairing organ damage or treating human diseases using iPSCs.
 

Pedro Pinto

Laboratory Lead, University of Greifswald – Medical Centre
Pedro Pinto

Pedro Pinto is currently leading the research lab affiliated with the Urology clinic of the University Hospital – Greifswald. He previously developed work on the applications the microphysiological systems, with AstraZeneca after his doctoral studies in Pharmaceutical Sciences at Utrecht University. His expertise is centered around renal in vitro models for either drug testing and disease modelling and since 2021 his research group is focusing on the study of kidney and prostate cancer pathophysiology with the use of microphysiological systems.

Philip Hewitt

Global head of early Investigative Toxicology, Merck Healthcare KGaA
Philip Hewitt

I originally trained as a Medical Biochemist at the University of Birmingham (1986-1989). I worked as a Research Assistant in the Pharmacology and Toxicology Department at Imperial College, London where I received my PhD in the lab of Dr Sharon Hotchkiss. The main theme of the research project was “percutaneous absorption: metabolic and kinetic parameters”. In 1996, I transferred to The University of California, San Francisco, in the Dermatology Department; I spent 18 months there under the guidance of Prof. Howard Maibach. In 1998 I started a permanent position in the Institute of Toxicology at Merck KGaA in Germany, where I established the Molecular Toxicology Group. I am currently responsible for early cytotoxicity screening, hepatotoxicity methods, biomarker monitoring, CYP induction studies, genotoxicity testing and cytokine screening. Alongside the routine screening, and mechanistic assays, I am leading the Merck assessment of more advanced cell models for safety testing and potential animal replacement. I work with several PhD students, on external collaborative projects and I am team representative on several internal pharmaceutical projects.

Robert Vries

CEO, Hubrecht Organoid Technology
Robert Vries

Robert received his PhD in Biochemistry from the Leiden University Medical Center on a molecular study of oncogenic transformation. He subsequently moved to Stanford University (USA) to do his Post Doc studying neural stem cells. Upon his return to the Netherlands he continued the study of adult stem cells in the group of Prof Hans Clevers at the Hubrecht Institute in The Netherlands.
In the group of Hans Clevers he was part of the team that developed the breakthrough technology that allowed the expansion of adult stem cells. The so-called Organoid Technology became the basis of the non-profit company ‘Hubrecht Organoid Technology’ (HUB) of which he is currently the CEO.
 

Stefan Przyborski

Professor, Durham University
Stefan Przyborski

Stefan has over 25 years experience in cell biology with specific interests in cell culture technology and bioengineering human tissues for in vitro applications. He has developed a multi-disciplinary approach to the bioengineering of tissue equivalents through creating bespoke devices and new cell culture platforms. Stefan holds an academic position as Professor in Cell Technology at Durham University. He is also a founder and the Chief Scientific Officer of Reprocell Europe, Glasgow, a biotechnology company that acquired cell technology he developed at Durham University UK. Stefan’s research continues to develop new innovative approaches to manage the growth and function of cultured cells in ways that more accurately reflect native tissues. These human tissue models have multiple applications and will be particularly relevant to modelling human disease, and advance basic research, safety screening and drug discovery.

Stephen J. Fey

Founder and Chief Research Officer, Celvivo
Stephen J. Fey

Stephen J. Fey

Founder and Chief Research Officer, Celvivo
Stephen J. Fey

Stephen J. Fey has a background in biomedical science having worked in research universities and companies for the past 30 years. He qualified for his PhD at Kings College, London University. He became a pioneer in 2D gel electrophoresis field and used this tool to study cervical cancer, diabetes and cardiovascular problems. He co-founded the Centre for Proteome Analysis at the University of Southern Denmark in 1997 (the world’s first purpose-built proteomics institute) and became CEO when the institute was spun out of SDU in 2006. Subsequently, he co-founded CelVivo in 2014, another spin out company, developing and commercialising 3D cell and tissue culture systems which mimic in vivo physiology and toxicology. He has 125 publications and has filed 37 patents.

Suzanne Fitzpatrick

SeniorAdvisor for Toxicology, FDA
Suzanne Fitzpatrick


Dr. Suzanne Fitzpatrick is the Senior Advisor for Toxicology at the US Food and Drug Administration. She is a board-certified toxicologist in the US and in Europe Dr. Fitzpatrick chairs the FDA’s Alternative Methods Work Group that is currently focusing on in vitro Microphysiological Systems. Dr. Fitzpatrick helped develop the FDA DARPA NCATS program on Organs on a Chip and continues to work and give presentations on this evolving area. Dr. Fitzpatrick is an Adjunct Professor at Johns Hopkins University. She received her BA from the University of California at San Diego and her PhD from Georgetown University.
 



 

Terry Van Vleet

Director of Investigative Toxicology, AbbVie
Terry Van Vleet

Dr. Van Vleet is currently the Director of Investigative Toxicology at AbbVie where he is responsible for Molecular and Computational Toxicology as well as In Vitro Platform Characterization for Preclinical Safety. He also serves as the discovery or development safety project representative on various drug development teams over diverse therapeutic areas. Prior to joining AbbVie, he worked at Bristol-Myers Squibb in positions of increasing responsibility including serving as the Head of Molecular and In Vitro Toxicology group. Dr. Van Vleet received his BS in Zoology (Chem minor) from Weber State University where he graduated summa cum laude. He received his PhD in Toxicology/Molecular Biology from Utah State University (graduating magna cum laude) where he studied the metabolism of procarcinogens by human airway cells. He later completed a Post-Doctoral Fellowship at the Medical University of South Carolina studying mechanism of renal toxicity with a focus on mitochondrial toxicity. Terry is a member of the Society of Toxicology (SOT), American College of Toxicology, and Royal Society of Biology and has published over 40 peer reviewed scientific manuscripts. He is also a Diplomate of the American Board of Toxicology, and a Fellow of the Academy of Toxicological Sciences. He is currently serving as the Past Chair of the IQ MPS Affiliate.

sponsors

Conference agenda

clock

8:00

Registration & Coffee

clock

9:00

Chair's Opening Remarks

Stefan Przyborski, Professor, Durham University

clock

9:10

Innovative Advanced Cell Technologies to Bioengineer Human Tissues In Vitro for Use in R&D and Modelling Human Disease

Stefan Przyborski, Professor, Durham University

  • Development of new cell culture devices and platforms to enhance cell growth in vitro
  • Generating highly specialized models of human tissues – examples of skin and intestinal mucosa
  • Modelling human disease – example, novel intestinal inflammatory tissue model of IBD
  • New innovations and developments to further enhance bioengineered tissue technology
  • clock

    9:50

    A model for assessing repeated-dose drug toxicity

    Stephen J. Fey, Founder and Chief Research Officer, Celvivo

  • Response to- and recovery from- treatment
  • Metabolic reprogramming
  • Clinostat cultures for keeping cells in a dynamic equilibrium

     

  • clock

    10:30

    Human tissue-specific extracellular matrix 3D models: a unique approach for novel target identification and drug screening

    Lisa Sassi, Scientist, Engitix Therapeutics

  • Development of decellularized tissue-specific extracellular matrix (ECM) scaffolds
  • Advantages of using ECM-based 3D models compared to two-dimensional models on plastic
  • Use of tissue-specific ECM hydrogels as a scalable and reproducible model to mimicking human disease, an overview
  • clock

    11:10

    Morning Coffee

    clock

    11:40

    Simple assays to measure Metabolism, Viability and Apoptosis in 3D cell cultures

    Darren Heywood, Product Manager, Promega UK Ltd

    • An overview of Promega’s cell health assay portfolio that can be used in 3D cultures
    • How assay multiplexing can provide more answers from each well
    • The use of real-time assays for kinetic monitoring of 3D cell health
     

    clock

    12:20

    3D Bioprinted Human Skeletal Muscle Models for In Vitro Physiological Drug Screening

    Hansjoerg Keller, Senior Principal Scientist, Novartis Institutes for BioMedical Research

  • In vitro human microphysiological assays boost drug development
  • 3D bioprinting enables the fabrication of complex human tissue in vitro models for drug discovery
  • 3D bioprinted human skeletal muscle models mimic pharmacological regulation of muscle contractile force
  • 3D bioprinted contractile human skeletal muscle models allow functional screening of test compounds
     
  • clock

    13:00

    Networking Lunch

    clock

    14:00

    Advancing Regulatory Science Through Innovation -- In Vitro Microphysiological Systems

    Suzanne Fitzpatrick, SeniorAdvisor for Toxicology, FDA

    • Regulation keeping pace with advances in basic and applied science and technology
    • Identifying modern toxicological tools that will improve preclinical safety predictions for regulatory use
    • Developing in vitro Microphysiological systems to bring innovative new technologies into the regulatory paradigm
    • Collaborating to develop organs-on-a-chip to screen for safe and effective products with more efficiency than current methods
     

    clock

    14:40

    HTS considerations for implementing complex co-culture models as secondary screening tools

    BanuPriya Sridharan, Investigator, GSK

  • Traditional HTS utilizes tumor cells in two-dimensional format that fail to recapitulate the complex tumor microenvironment (TME) morphology and do not translate well to in vivo and clinical outcomes
  • We developed a versatile triculture model of NSCLC that incorporates cancer associated cells such as normal lung fibroblasts and normal bronchiolar epithelial cells, and, components of the extracellular matrix (ECM), in the context of developing robust, scalable and functional assays
  • To assess cytotoxicity, tumor cell viability was determined via cell Titer-Glo or inherent GFP expression in the tumor cells by high content analysis (HCA)
  • This allowed the screening of PARP inhibitors across drug sensitive and resistant cell lines in traditional versus triculture platforms
     
  • clock

    15:20

    Implementation of Organoids and Microphysiological systems for pre-clinical drug discovery

    Jason Ekert, Senior Director and Head of Complex In Vitro Models, GlaxoSmithKline

  • Development of an Organoid workflow and platform
  • Latest progress in qualifying and implementing disease relevant and safety models using organoids and microphysiological systems
  • Highlight the activities of consortia to help drive standardization of MPS
     
  • clock

    16:00

    Afternoon Tea

    clock

    16:30

    HUB Organoids™: a revolutionary patient-derived in vitro model for drug screening and patient stratification

    Robert Vries, CEO, Hubrecht Organoid Technology

  • The discovery of adult stem cells allowed the development of patient-derived HUB Organoids
  • HUB Organoids revolutionize 3D cultures by bringing patients in the lab and improving translatability and predictivity
  • HUB Organoids are a robust, scalable, and reproducible system for drug screening
  • The future of personalize medicine: HUB Organoids as a diagnostic tool
  • clock

    17:10

    Assessing the applicability of 3D human liver spheroids in early safety screening

    Freddy Van Goethem, Scientific Director, Fellow, Janssen (Johnson & Johnson)

  • The use of 3D liver spheroids to predict drug-induced liver injury, an introduction.
  • Exploring the applicability of transcriptomic profiling.
  • Proof of concept study
     
  • clock

    17:50

    Chair’s Closing Remarks and Close of Day One

    Stefan Przyborski, Professor, Durham University

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chair's Opening Remarks

    Philip Hewitt, Global head of early Investigative Toxicology, Merck Healthcare KGaA

    clock

    9:10

    Renal microphysiological systems: where are we now?

    Pedro Pinto, Laboratory Lead, University of Greifswald – Medical Centre

  • MPS in research and development
  • Advantage of MPS models
  • Practical applications of MPS
     
  • clock

    9:50

    Growing human bone in a bone-on-chip

    Elisa Budyn, Mechanical Engineering, Ecole Normale Supérieure Paris-Saclay

  • New bone formation by human mesenchymal stem cells (MSCs) in vitro is a challenge. A bone-on-chip based on human decellularised native bone is proposed as a physiologically relevant 3D environment for human bone cell recellularization
  • The bone-on-chip successfully led to stem cell derived osteocytes (SCDOs) from either primary adult MSCs or foetal osteoblast progenitors. FTIR and histo-chemistry showed the cells produced a mineralised collagen matrix mimicking the chemical heterogeneity of native bone. Confocal microscopy showed the matrix’ layered microstructure
  • Fluorescent microscopy showed the cells adapted their calcium response to the expected in vivo mechanical stimulations at different stages of differentiation. The new bone displayed a flexural modulus ranging from 25 to 100% of the decellularised bone stiffness between 109 and 126 days
  • The bone-on-chip offers promising opportunities for organ culture up to over 26 months for bone formation study, cell diagnosis or cell reprogramming
     
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Advanced intestinal models for preclinical safety: validation of an organ-on-a-chip system for early screening

    Philip Hewitt, Global head of early Investigative Toxicology, Merck Healthcare KGaA

  • Comparison of 2D, 3D and OOAC cell models: which context of use is each is fit for
  • Assessment of iPSC derived colon organoids
  • Pre-validation and implementation of OOAC small intestine model (CaCo2)
  • Future perspectives and more complex intestinal models?
     
  • clock

    11:40

    Development and adoption of 3D and microphysiological systems for drug safety assessment

    Caroline Archer, Associate Principal Scientist, AstraZeneca

  • Outline the context of use of microphysiological systems (MPS) to generate safety and efficacy data for drug development with improved clinical relevance over more traditional 2D cell culture and animal models
  • Highlight examples of data generated from these systems that demonstrate the utility of MPS for safety assessment
  • Current challenges to the adoption and/or development of MPS in the pharmaceutical industry

     

  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Complex in vitro models: a scientific and 3Rs perspective

    Catherine Vickers, Head of Innovation, NC3Rs

    Overview of resources provided by the NC3Rs to support the development and adoption of complex in vitro models
    Case studies from our portfolio
    Perspectives on 3Rs benefits now and in the future
     

    clock

    14:00

    3D uHTS Models for Chemo Response Profiling of Cancer

    Louis Scampavia, Scientific Director, Sr, Scripps Research

  • 3D Pancreas and Brain Cancer Modelling
  • 3D Technology and HTS Protocol
  • Primary cell isolation from patients
  • Screening the NCI Oncology Drug Set
  • Dose Response results
  • Drug Gene Network Analysis
  • Synergy studies
     
  • clock

    14:40

    An immunological tumour infiltration platform for target discovery

    Julian Bahr, Senior Scientist, AstraZeneca

  • Developing a novel three-dimensional spheroid-splenocyte co-culture system
  • Recapitulating in vivo immune infiltration phenotypes by four-color imaging of the co-culture
  • Efficient CRISPR-mediated gene KO in the co-culture system
  • Evaluation of a CRISPR KO screen for immunological tumour infiltration targets using high content imaging
  • clock

    15:20

    Afternoon Tea

    clock

    15:50

    Application/Characterization of Organ-on-a-Chip Platforms from Preclinical Species in Drug Safety and ADME Testing

    Terry Van Vleet, Director of Investigative Toxicology, AbbVie

  • The need and applications for animal cell-based chips in safety assessment of drugs
  • Challenges and barriers to building chips from animal cells
  • An approach to building animal cell chips, the outcome of that effort, and lessons learned
  • Need for improved value compared to spheroids for increased cost/time
  • clock

    16:30

    Organoid cellular cancer immunity model in motion

    Anne Rios, Principal Investigator/ Head of the PMC imaging center, The Princess Maxima Center of Pediatric Oncology

  • How advances in organoids have created new possibilities in the development of human cancer models
  • Utilising novel in vitro technologies to translate cancer research into new treatments more efficiently
  • Modelling cell-to-cell interactions in the tumor microenvironment (TME), to better reflect cancer and drug progression
  • The movement towards modeling patient-specific cancer immunity mechanisms
  • clock

    17:10

    Chair’s Closing Remarks and Close of Day Two

    Philip Hewitt, Global head of early Investigative Toxicology, Merck Healthcare KGaA


    Principal Investigator/ Head of the PMC imaging center
    The Princess Maxima Center of Pediatric Oncology
    Principal Investigator/ Head of the PMC imaging center
    The Princess Maxima Center of Pediatric Oncology
    Investigator
    GSK
    Associate Principal Scientist
    AstraZeneca
    Head of Innovation
    NC3Rs
    Product Manager
    Promega UK Ltd
    Mechanical Engineering
    Ecole Normale Supérieure Paris-Saclay
    Scientific Director, Fellow
    Janssen (Johnson & Johnson)
    Senior Principal Scientist
    Novartis Institutes for BioMedical Research
    Field Application Specialist
    CELLINK
    Senior Director and Head of Complex In Vitro Models
    GlaxoSmithKline
    Senior Scientist
    AstraZeneca
    Scientist
    Engitix Therapeutics
    Scientific Director, Sr
    Scripps Research
    CSO Newcells Biotech and Professor of Stem Cell Sciences Newcastle University
    Newcells Biotech Limited
    Laboratory Lead
    University of Greifswald – Medical Centre
    Global head of early Investigative Toxicology
    Merck Healthcare KGaA
    CEO
    Hubrecht Organoid Technology
    Professor
    Durham University
    Founder and Chief Research Officer
    Celvivo
    Founder and Chief Research Officer
    Celvivo
    SeniorAdvisor for Toxicology
    FDA
    Director of Investigative Toxicology
    AbbVie

    Sponsors and Exhibitors

    Sponsors

    Official Media Partner

    Supporters

    Workshops

    Reducing attrition in drug discovery through the use of human translational cellular models
    Workshop

    Reducing attrition in drug discovery through the use of human translational cellular models

    Online Virtual Event
    8 February 2022
    Online Virtual Event , United Kingdom

    Bioprinting for 3D Cell Culture
    Workshop

    Bioprinting for 3D Cell Culture

    Online Virtual Event
    8 February 2022
    Online Virtual Event , United Kingdom

    Speaker Interview - Julian Bahr, AstraZeneca

    Download

    Speaker Interview - Elisa Budyn, Ecole Normale Supérieure Paris-Saclay

    Download

    Speaker Interview - ROBERT VRIES, Hubrecht Organoid Technology

    Download

    Speaker Interview - Terry Van Vleet, AbbVie

    Download

    Chair Letter

    Download

    Chair & Speaker Biographies

    Download

    Detailed Agenda

    Download

    Agenda at a Glance

    Download

    3D Cell Culture 2022 Brochure

    Download

    Past Attendees

    Download

    Past Speaker Presentation – Promega

    Download

    Past Speaker Presentation – Mimetas

    Download

    Past Speaker Presentation – Merck

    Download

    Past Speaker Presentation – FDA

    Download

    Past Speaker Presentation – CelVivo

    Download

    Past Speaker Presentation - Aurelia Bioscience

    Download

    Past Speaker Presentation – University of Southampton

    Download

    Past Speaker Presentation - NC3Rs

    Download

    Sponsors and Exhibitors


    Allevi

    Sponsors and Exhibitors
    http://www.allevi3d.com/

    Allevi 3D bioprinters and bioinks are used by leading researchers worldwide to find solutions to humanity’s most difficult problems—to cure disease, to test novel drugs, to eliminate the organ waiting list, to build with life. Allevi became part of the 3D Systems family in 2021 as part of the company’s strategic growth in advanced bioprinting and regenerative medicine. Our mission is to make it easy to design and engineer 3D tissues. Allevi by 3D Systems is trusted by leading researchers and industry giants in hundreds of labs worldwide. We are constantly inspired by our community of users who are performing world-class research on our platform.

    Sponsors


    CelVivo

    Sponsors
    https://celvivo.com/

    CelVivo provide a 3D Cell Culture technology mimicking in vivo performance.

    The CelVivo system creates an environment which promotes the growth and maintenance of large 3D tissue mimetic structures, whether they are spheroids, organoids, acini and other aggregates.

    Our ambition is to provide cells with conditions which allow them to develop functionality which closely mimics that seen in the intact organism. To achieve this, we have developed a system which obviates the need for scaffolds, gels or any type of additives which might perturb gene expression away from its natural baseline equilibrium. Furthermore, we have very significantly reduced contact with plastics and reduced shear forces.



    Promega

    Sponsors
    http://www.promega.com

    Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 4,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification.

    Promega products are used by scientists asking fundamental questions about biological processes and applying scientific knowledge to diagnose and treat diseases, discover new therapeutics and for use in genetics and DNA testing.

    Founded in 1978, the company is headquartered in Madison, USA, with branches in 16 countries including Southampton UK and over 50 global distributors.


    Media Partners


    Genetic Engineering News

    Official Media Partner
    http://www.genengnews.com

    Genetic Engineering & Biotechnology News (GEN) is the most authoritative and widely read biotechnology news publication in the world.Published 21 times a year,GEN's unique news and technology focus include the entire bioproduct life cycle from early-stage R&D to applied research and bioprocess through to commercialization. GEN is the only publication that provides the full range of the biotechnology market coverage in areas such as omics, drugs and biomarker discovery, bioprocessing, clinical research, molecular diagnostics and biobusiness. For a free subscription go to: http://www.genengnews.com/subscriptions.aspx


    3DMedNet

    Official Media Partner
    https://www.3dmednet.com/

    3DMedNet is an online community providing the latest news, opinions and peer-reviewed journal articles focused on the applications of 3D printing technologies in medicine, including 3D-printed medical devices, surgery, pharmaceuticals, bioprinting, dentistry and the regulatory landscape. Visit 3DMedNet today at: www.3dmednet.com

    Media Partners


    MedTube

    Supporters
    https://medtube.net/



    IPI

    Supporters
    http://www.ipimediaworld.com

    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    BioChem Adda

    Supporters
    https://www.biochemadda.com/

    BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!


    American Pharmaceutical Review

    Supporters
    http://www.americanpharmaceuticalreview.com

    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

    Online Virtual Event

    Online Virtual Event
    United Kingdom

    Online Virtual Event

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.